
About Covis
At Covis, our paramount concern is patients’ outcomes as we focus on improving the health of people with serious medical conditions.
Covis is always evaluating products and corporate acquisition opportunities. Covis is well-capitalized and has significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities.
Click here to access our California Compliance Statement and Declaration.
18 Brands in the current portfolio
Sold in 50+ countries
Long-term supply agreements with 10+ manufacturers ensuring supply chain security
Values
The ethos at Covis Pharma is focused on five key pillars:
Collaboration
With all stakeholders ensuring access to their ‘best in class’ products for all patients, including those in most need
Diversification
Firm believers in corporate diversity
Development
Focusing on developing and extending therapeutic solutions for patients and physicians globally, and professional growth for employees and partners
Entrepreneurial
Striving to create new opportunities that deliver results for all stakeholders
Integrity
Strong governance and compliance, to ensure ethical behaviour in all interactions and work they do
Team
Michael Porter
Chief Executive Officer
Martin Cepeda
Chief Human Resources Officer
Raghav Chari
Chief Innovation Officer
Chad Collins
Vice President & General Manager, U.S. Business
Albert Dahouk
Chief Information Officer
Fabio Fazio
Global Head of Quality
Nick Kelly
Senior Vice President, Supply Chain
Ozgur Kilic
Chief Financial Officer
Christine Poulin
President, North America & General Manager of Canada
Francesco Tallarico
General Counsel & Head of Government Affairs & Policy
Ronald van der Rol
Vice President, Global Head, Commercial
Daniel Freedman, Ph.D.
Vice President of Clinical Operations
Janine List
Vice President, Head of Business Planning and Analysis
Sara Mastandrea
Vice President, Chief Accounting Officer & Treasurer
Emanuele Pizzo
Vice President, Finance, EU and International
Andrew Teehan
Vice President and Associate General Counsel
Rajiv de Silva
Chairman
Bruno Bagnouls
Products and Innovation Group Head, Alter Domus
Gaetan Dumont
Apollo Advisor and Founder of The Square Finance
Ibrahim Jabri
Director, Alter Domus
Michael Porter
Chief Executive Officer, Covis Pharma
Xavier Rouviere
Senior Legal Manager and Team Leader, Alter Domus
Michael Saffer
Principal, Apollo Global Management
Elan Carr
Consultant to various industries and organizations
Sam Feinstein
Partner, Apollo Global Management
John J. Kiely
Director, Zovio Inc. & Amneal Pharmaceutical
Barry Levinson
Managing Director, Princeton Biopharma
Clinton Lewis
Former EVP and Group President, Zoetis
Caroline Manogue
Former EVP and Chief Legal Office, Endo Pharmaceuticals
Partnerships
We partner with the world’s leading pharmaceutical companies and contract manufacturing organizations to deliver an uninterrupted supply of high-quality pharmaceuticals.
Operational Capabilities
Covis has unparalleled expertise across all functional areas with a flawless history of executing commercial onboarding, tech transferring, and launching authorized generic and line extension products.
Business Development
Covis is always evaluating products and corporate acquisition opportunities with significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities. For all partnering inquiries, please contact us.
Product Development
Covis is devoted to developing new therapeutic solutions to improve patients’ quality of life through line extensions of its existing portfolio as well as selected novel late-stage clinical programs.
Our Operating Partners












Our Business Development Partners










Our Authorized Distributors of Record
Asia-Pacific






Europe




United States



Brazil and Mexico

South Africa

Michael Porter
Chief Executive Officer
Michael Porter is the Chief Executive Officer of the Covis Group and a member of the Board. Mr. Porter was involved in the original founding of Covis as the Senior Operating Executive and a member of the Board responsible for original sourcing, investment thesis and the forming of Covis in 2011 with initial complex carve-out from GlaxoSmithKline. Mr. Porter was previously COO of Covis in 2013 then became CEO in 2015, responsible for the execution and consummation of the partial monetization of the business for $1.2 billion in 2015 and the subsequent sale to Apollo in 2020 for ~$700 million.
Mr. Porter began his career at AlixPartners, LLP in its Turnaround and Performance Improvement Group. Prior to joining Covis, Mr. Porter was a Senior Operating Executive of Cerberus Capital Management, L.P. and has also worked with another large distressed private equity fund. Mr. Porter has over 20 years of experience in private equity and speaks English, Spanish, Portuguese, French, Japanese, and Russian. Mr. Porter received his M.B.A. from Columbia University with a concentration in Finance via the accelerated program. In addition, Mr. Porter studied International Business at Senshu University in Kawasaki, Japan.
Martin Cepeda
Chief Human Resources Officer
Martin Cepeda is the Chief Human Resources Officer of Covis Pharma. Prior to joining Covis, Martin worked at AstraZeneca as Head of Human Resources for the Europe Oncology Business, based in Zug, Switzerland, >$2 billion in annual revenue and ~1,750 employees. He was also a member of AstraZeneca’s Inclusion and Diversity (I&D) Council chaired by the CEO, driving the company’s global I&D strategy. Martin brings over 16 years of Global HR experience across multinational pharmaceutical and life science companies.
Prior to AstraZeneca, Martin worked in HR roles of increasing responsibility at Johnson & Johnson and Wyeth (acquired by Pfizer in 2009). In those companies, he held roles in HR Data, Insights and Analytics, Talent Acquisition, and various HR Business Partner roles based in the U.S. and Europe.
Martin received his B.S. in Business Management from Penn State University and his MBA in International Business from Villanova University, both located in the U.S.
Raghav Chari
Chief Innovation Officer
Raghav Chari has 25 years’ experience in the biopharmaceutical arena. Over this period, he has successfully built and led small and large organizations across the R&D and commercialization continuum.
Over the last 5 years, he has founded and continues to be involved in several startups that work at the interface between drug discovery and technology. All these startups seek to improve how novel products are discovered and developed by utilizing approaches involving machine learning, quantum mechanics and various technologies for personalized medicine.
From 2009 through 2016, he was President of Promius Pharma, a dermatology and neurology company, and Executive Vice President of Proprietary Products at Dr. Reddy’s Laboratories. In this role he built an integrated R&D and Commercial business which led to several first cycle NDA approvals for products that were developed organically from inception through commercial launch.
He has also been responsible for over 50 licensing and product development deals in the biopharmaceutical space. Early in his career, Raghav worked at McKinsey and Company, followed by stints at two small drug discovery/early development-stage biotech companies where he played hybrid R&D and commercial roles.
Raghav has a PhD in Physics from Princeton University, and a BS in Mathematics from the California Institute of Technology.
Fabio Fazio
Global Head of Quality
Fabio Fazio is the Global Head of Quality. He ensures compliance of pharmaceutical production to good manufacturing practice and to Marketing Authorizations. Fabio is responsible for the implementation of the quality systems which include the management of regulatory inspections, supplier oversight and audits, technology transfers, and adherence to good distribution practice.
Prior to Covis, Fabio worked at Biogen Idec as Qualified Person and in other technical CMC roles. Previous experiences encompass Process Development at GlaxoSmithKline in support of early stage clinical trials and basic research of novel therapeutic agents at the Scripps Research Institute in La Jolla, CA.
Fabio graduated from the Faculty of Pharmacy at the University of Siena, Italy, and received his Ph.D. in Chemistry from the University of Wuppertal, Germany.
Christine Poulin
President, North America & General Manager of Canada
A leading pharmaceutical professional with in-depth expertise across marketing, sales, product management, stakeholder relations, and communications, Christine brings more than 25 years of Pharmaceutical Industry experience in leading organizations to her role of President in North America and General Manager for Covis in Canada.
Prior to joining the Company, Christine served as the General Manager, Canada at Teva Pharmaceuticals, where she had full P&L and leadership responsibility for a CAD $1 billion dollar business. Prior to Teva, Christine has held roles of growing responsibility in leading organizations, namely Teva, Pfizer, Sanofi in sales, marketing, and medical communications, moving to leadership positions. Her evolving education and industry expertise allows her to successfully support and manage her team to develop, launch and support pharmaceutical products and business development.
Christine holds a Masters of Business Administration (M.B.A.) from l’École des Hautes Études Commerciales, a Bachelor of Commerce from McGill University, and has completed leadership development courses at the McGill Executive Institute and the Advanced Management Program at Wharton School of the University of Pennsylvania.
Nick Kelly
Senior Vice President, Supply Chain
Nick Kelly is the Senior Vice President of Supply Chain. He has over 20 years of supply chain experience as a management consultant across multiple industries as well as within the pharmaceutical industry across branded, generics and medical device organizations.
Prior to Covis, Nick held several senior management roles at the regional & global level within the pharmaceutical industry, including Cardinal Health, Teva and Johnson & Johnson.
He has solid strategic, tactical and operational management experience, developing and maintaining relationships across the E2E supply chain to ensure an efficient operation.
Nick attended the University of Westminster where he received his BSc (Hons) in Business Information Technology.
Ozgur Kilic
Chief Financial Officer
Ozgur Kilic is the Global CFO of Covis Pharma. Previously Ozgur was the CFO of Vertice Pharma, a specialty generic pharma company in the U.S., backed by Warburg Pincus. Ozgur brings over 17 years of healthcare finance experience ranging from branded and generic pharmaceuticals to vaccines and medical devices both in the U.S. and Europe.
Prior to Vertice, Ozgur spent 14 years at Novartis in progressive Finance roles including Country and Region CFO roles in Switzerland, U.K., Italy and the U.S. He has significant experience in partnering with commercial, manufacturing, R&D and BD&L / M&A teams at operational and strategical level to drive business results.
Ozgur received his B.A. in Business Administration from Koc University in Turkey, MBA in Finance and Investment with distinction from Stuttgart Institute of Management Technology (SIMT), Germany and Executive Education in Finance from Harvard Business School. Ozgur is a Chartered Management Accountant (CIMA UK) and speaks English, Turkish, Italian and German.
Francesco Tallarico
General Counsel & Head of Government Affairs & Policy
Francesco Tallarico is the General Counsel & Head of Government Affairs & Policy of Covis Pharma Group.
Prior to joining Covis, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at The Flowr Corporation, a federally licensed global cannabis producer listed on the TSX-V. At Flowr, Mr. Tallarico managed all aspects of the legal and regulatory function of the company, including having led the company's M&A and corporate finance transactions valued at over CAD$340 million.
Prior to Flowr, Mr. Tallarico served as the Chief Legal Officer and Corporate Secretary at Concordia International Corp. (now Advanz Pharma), a global specialty pharmaceutical company previously listed on the TSX and NASDAQ. At Concordia, Mr. Tallarico led the global legal and compliance functions, including having led Concordia's M&A transactions valued at over USD$4.5 billion and corporate restructuring that resulted in Concordia reducing its debt by approximately USD$2.4 billion. Before joining Concordia, Mr. Tallarico practiced law in Toronto at Fasken Martineau DuMoulin LLP, specializing in corporate finance, M&A and securities matters.
Mr. Tallarico received his Bachelor of Arts from the University of Toronto and his Juris Doctor from the University of Windsor.
Albert Dahouk
Chief Information Officer
Albert Dahouk is the global Chief Information Officer (CIO) of Covis Pharma. Prior to joining, Albert was an executive partner of a global management consulting firm, with a focus on the Pharma and Financial sectors.
He has worked for several fortune 100 companies where he held various senior executive roles. Albert delivered successful strategies and innovation solutions which helped transform global companies to face today’s market challenges. He brings over 30 years of technology consulting and corporate experience ranging from Telecommunication, Financials, Leisure and Pharma sectors across the Americas, EMEA and APAC regions.
Prior to starting his career as an entrepreneur, Albert spent 20 years in executive roles in innovative corporations where he gained significant experience in building and transforming IT organizations, partnering with internal and external stakeholders, and shaping innovative solutions for their market to drive successful results.
Beside his extensive knowledge in legal and compliance topics, Albert holds a B.S in Mathematics, B.S. in Computer Science and an MBA in Technology Management and speaks several languages, beside his native English. He is a true global leader.
Chad Collins
Vice President & General Manager, U.S. Business
Chad Collins is the Vice President, US Head of Market Access for Covis Pharma. He has more than 20 years of commercially focused US and Global industry experience. Prior to joining Covis, Chad worked for Sanofi and Bausch Health in several commercial roles in these organizations, and his most recent role was the Vice President of Market Access at Bausch and Lomb.
During his time in the industry he held positions in sales, sales leadership, account management, strategy, brand leadership, along with experiences in owning all channels of business and contracting and analytics and customer service. Chad is a graduate of Hardin Simmons University where he double majored in Management and Marketing. Chad also holds an MBA from the University of Houston.
Daniel Freedman, Ph.D.
Vice President of Clinical Operations
Dan Freedman is the Vice President of Clinical Operations and Asset Lead for Ciraparantag. Dan has over 25 years of experience in building and working with cross-functional drug development teams through pre-clinical, clinical, and post-marketing development.
Prior to joining Covis, Dan held roles in Research, Clinical Operations, Regulatory Affairs, and Program Management developing small molecules, biologics and small interfering RNAs across several therapeutic areas at AMAG, Alnylam, Vertex and Biogen.
Dan received his Ph.D. in Molecular and Cellular Biology at the University of Massachusetts and completed his postdoctoral training in the Biological Chemistry and Molecular Pharmacology Department at Harvard Medical School.
John McKenney
Vice President, US Strategic Accounts
John McKenney is the Vice President, US Strategic Accounts and leads the GPO, IDN and DOD contracting business in the US. He brings over 25 years of experience focused on market access, business development and commercial sales. Prior to Covis, John was with AMAG Pharmaceuticals as the Executive Director and Head of Strategic Accounts leading GPO and IDN contracting across both the Oncology and Women's Health franchises. His expertise in market access spans across several industry leading organizations with increased responsibilities with Guardant Health, R-Pharm US, Dendreon, Sanofi, Johnson & Johnson, Boehringer Ingelheim, Alza, and Vivus. John started his career at TAP Pharmaceuticals.
John received his Bachelor of Applied Science from San Diego State University - California State University.
Rajiv de Silva
Chairman
Mr. Rajiv De Silva is the Managing Partner of Asiri Advisors, a firm focused on advising private equity, and other corporate and financial institutions on the biopharmaceutical sector. He has broad international experience, having managed businesses in the United States, Europe, Canada, Latin America, Asia, South Africa and Australia.
He was President, Chief Executive Officer and Director of Endo International, Plc, a publicly traded multinational pharmaceutical company, from 2013 to 2016. Prior to joining Endo, he served as the President of Valeant Pharmaceuticals International, Inc. from 2010 to 2013 and served as its Chief Operating Officer, Specialty Pharmaceuticals from 2009 to 2013. Prior to joining Valeant, Mr. De Silva held various leadership positions with Novartis AG. He served as President of Novartis Vaccines USA and Head, Vaccines of the Americas at Novartis. Mr. De Silva also served as President of Novartis Pharmaceuticals Canada. He originally joined Novartis as Global Head of Strategic Planning for Novartis Pharma AG in Basel, Switzerland. Prior to his time at Novartis, Mr. De Silva was a Partner at McKinsey & Company and served as a member of the leadership group of its Pharmaceuticals and Medical Products Practice. Mr. De Silva was a Director of AMAG Pharmaceuticals, Inc. from 2012 to 2013. He served on the Board of Rx&D, the Canadian Pharmaceutical Association from 2005 to 2007, was a member of the Board of Trustees of The Kent Place School in Summit, NJ, and is currently a member of the Board of Trustees and Treasurer of The Gill St. Bernard's School in Gladstone, NJ.
Mr. Rajiv holds a BSE, Honors from Princeton University, an MS from Stanford University and an MBA with Distinction from the Wharton School at the University of Pennsylvania.
Bruno Bagnouls
Products and Innovation Group Head, Alter Domus
Bruno joined AlterDomus in May 2019, and leads global Sales and Relationship Management efforts, as well as the development and implementation of new products and innovation. Previously, Bruno was the Global Head of Private Equity and Real Estate at TMF Group, where he acquired experience in the implementation, management, accounting and administration of private equity and real assets funds and SPVs. Prior to this, Bruno was Head of Corporate Services at AlterDomus for 15 years. Bruno has a degree in Business Studies from IPAG in Paris (as well as in French Accounting).
Gaetan Dumont
Apollo Advisor and Founder of The Square Finance
Gaetan is an Apollo Advisor in Luxembourg who also founded The Square Finance, a privately owned advisory company focused on providing corporate finance, treasure services, compliance, risk management, corporate governance, process and internal organizational services to clients. Gaetan serves as a professional independent director and is certified from various risk management organizations and was the Treasury Manager of the Year in 2016 in the Luxembourg Finance Awards. Gaetan is a member of the board of the ILA (Luxembourg Directors Institute) and ATEL (corporate treasurers). Gaetan has requisite pharma experience as a board member of the Lux board of the UCB group. Gaetan has a degree from HEC Liege University.
Ibrahim Jabri
Director, Alter Domus
Ibrahim Jabri joined AlterDomus in December 2014 and is a director in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Ibrahim worked for 6 years at PwC Luxembourg in the audit and tax and accounting departments. He also worked at Capital Fiduciary Group. Ibrahim holds a degree in Business Administration from UCL Mons, Belgium and is a member of the Luxembourg Ordre des Experts Compatables (chartered accountants)
Xavier Rouviere
Senior Legal Manager and Team Leader, Alter Domus
Xavier joined AlterDomus in October 2016 and is a Team Leader in the Private Equity and Infrastructure segment based in Luxembourg. He serves as a board member for other multinationals and Private Equity firms. Before AlterDomus, Xavier worked JP Morgan Bank Luxembourg as a Company Administration Manager. Xavier has multiple degrees from University of Nancy in France. Xavier is on the Lux boards of Verallia and Watches of Switzerland.
Michael Saffer
Principal, Apollo Global Management
Mr. Saffer is a Principal in the London Private Equity team at Apollo, having joined in 2015. Since he joined Apollo, Mr. Saffer has been involved in various private equity transactions, including OLB, Catalina, Aspen and Gamenet. Mr. Saffer currently serves on the board of directors of Aspen and Gamenet.
Previously, Mr. Saffer was a member of the M&A group at Credit Suisse based in London.
Mr. Saffer graduated from the University of Nottingham with a BSc in Economics.
Elan Carr
Consultant to various industries and organizations
With experience as a senior U.S. diplomat, corporate lawyer, criminal prosecutor, and military officer, Elan Carr provides a diverse set of skills and an influential voice on global issues affecting both public policy and the private sector. He serves as a visiting fellow at the Heritage Foundation, a teaching fellow at the University of Southern California, and a member of both for-profit and non-profit boards of directors.
In 2019, Mr. Carr was appointed United States Special Envoy to Monitor and Combat Anti-Semitism. As the senior diplomatic representative of the United States and the chief advisor to the Secretary of State on the subject of anti-Semitism, he directed America’s global policies and programs aimed at combating it. While in office, he negotiated groundbreaking agreements with foreign governments, convened the first-ever U.S. Government-sponsored conference on combating online hate, and focused the attention of foreign and domestic law enforcement leaders on the importance of hate crimes prosecutions. During his tenure, his office was voted by Congress to be given the rank of Ambassador.
Prior to his federal appointment, Mr. Carr prosecuted violent felony crimes for more than a decade as a Deputy District Attorney for Los Angeles County. He prosecuted murders, sexual assaults, child molestations, and cases involving Southern California’s most notorious criminal street gangs. He was also one of LA County’s few specially-designated animal cruelty prosecutors.
As a private sector attorney, Mr. Carr represented major corporations in general commercial litigation, intellectual property litigation, and white collar criminal defense at leading corporate law firms, including Irell & Manella and Epstein Becker & Green in Los Angeles, and Kaye, Scholer, Fierman, Hays & Handler in New York.
Mr. Carr is an officer in the United States Army Reserve and received multiple awards for his two decades of military service. In 2003-04, he spent nearly a year on military deployment in Iraq, where he helped to lead a joint anti-terrorism team in life-saving missions and prosecuted terrorists. He also helped to establish an independent Iraqi judiciary and trained Iraqi judges on constitutional law and criminal defense.
Mr. Carr holds a B.A. in philosophy and political science, with honors, from the University of California Berkeley and a J.D. from the Northwestern University School of Law. He is married to Dr. Dahlia T. Carr, a rheumatologist in private practice, and they have three children, Hannah, Rachelle, and Samuel.
Sam Feinstein
Partner, Apollo Global Management
Mr. Feinstein is a partner of Apollo, where he has been employed since 2007, and is focused on Apollo's investments in the chemicals and pharmaceuticals sectors. Previously, he was a member of the Investment Banking Group at Morgan Stanley. Mr. Feinstein currently serves on the board of directors of Covis Pharma and Vacuumshmelze GmbH & Co., and formerly served on the board of directors CEVA Logistics, Hexion Inc., Momentive Performance Materials, Pinnacle Agriculture Holdings, Taminco Global Chemicals and VECTRA Co.
John J. Kiely
Director, Zovio Inc. & Amneal Pharmaceutical
Mr. Kiely is a director of two public companies, Zovio Inc., an educational technology company, and Amneal Pharmaceutical, a generic and specialty pharmaceutical company. For both companies, he serves as Audit Committee Chair, and as a member of the Nominating Committee. Mr. Kiely is also a director of the Partnership for A Healthier America, a nonprofit organization.
Mr. Kiely retired from PricewaterhouseCoopers LLP in 2019 where during his 39-year career he had significant leadership roles, including Assurance Chief Quality Officer, Assurance Leader of the Private Equity Sector, and Leader of the U.S Pharmaceutical Industry Sector. During his PwC career, he had extensive experience working with Fortune 500 companies and Private Equity portfolio companies.
Mr. Kiely earned a B.A. from St. Francis University (Pa) and is a certified public accountant.
Barry Levinson
Managing Director, Princeton Biopharma
Mr. Levinson is a Managing Director at Princeton Biopharma Capital Partners, LLC with over 25 years of biotech and pharmaceutical industry experience combined with a distinguished scientific career. Prior to joining Princeton Biopharma Capital Partners, LLC, Mr. Levinson was Vice President of Business Development at Valeant Pharma North America LLC, responsible for the business development activities of its specialty pharmaceutical businesses in dermatology, CNS, orphan conditions and ophthalmology. Before Valeant, Mr. Levinson was a founding employee of Aton Pharma, Inc., a specialty pharmaceutical company with products that treated orphan conditions and ophthalmology. As its Vice President of Business Development, Mr. Levinson identified and acquired several key products for Aton and put in place its international partnerships. In addition, he was responsible for recognizing opportunities to expand the application of Aton's products to new medical uses, and spearheaded programs to develop these new indications.
Before Aton, Mr. Levinson was Founder and President of Park Life Science Advisory, LLC, where he provided outsourced business development capabilities for life science companies. He was previously a Managing Director at CPP Advisors (now Apeiron Partners), a boutique life sciences strategic advisory group and before that a Director in the Life Sciences Group at KPMG Corporate Finance, LLP, an investment bank. For the 10 years prior to KPMG, Mr. Levinson held increasingly senior positions in cardiovascular research and then in business development at Berlex Laboratories, the US subsidiary of Schering A.G. (now Bayer Healthcare Pharmaceuticals), most recently as Associate Director of Schering's Office of Technology. Before Berlex, Mr. Levinson initiated and developed the Protein Biochemistry Group at the biotech startup Ecogen, and served as the company's Radiation Safety Officer. Mr. Levinson received his PhD and Master's degrees in Molecular Biophysics and Biochemistry from Yale University, and was granted his BA, with highest honors, in Biochemistry from Princeton University.
Clinton Lewis
Former EVP and Group President, Zoetis
Clint Lewis has over 30 years of experience in the life sciences, healthcare and pharmaceutical industry having previously held senior executive positions across both human health and animal health at Pfizer and Zoetis. He has worked and resided both in the U.S. and in Europe with extensive international travel.
As Executive Vice President and Group President, International Operations and Commercial Development for Zoetis, Clint served as a corporate officer and member of the Executive Management Team, responsible for setting the over-arching strategy and capital allocation plan for the company. Clint was responsible for all markets outside of the United States with operations in 45 countries and a workforce of over 3,500 people.
Previously, Clint served as the Executive Vice President and President of U.S. Operations at Zoetis. In this role, Clint had responsibility for a $2.5 billion business and a workforce of over 1,200. Clint helped lead the successful spin-out and IPO of Zoetis out of Pfizer in 2013. He played a critical role leading the global commercial restructuring, eliminating ~40% of SKUs, exiting 25 markets and reducing SG&A 30% resulting in a cost savings of $180 million.
Prior to the formation of Zoetis, Clint spent 25 years in senior commercial roles of increasing responsibility at Pfizer, Inc. across both human and animal health. Clint currently serves as a member of the Board of Directors for International Paper (NYSE: IP) and serves on the Board's Governance and Public Policy & Environment sub-committees.
The National Agri-Marketing Association recognized Clint as the Top Agri-Business Leader in the U.S. in 2015. Clint has been profiled in CEO International magazine (Sept. 2016); Black Enterprise Top African Americans in Corporate America (2015) and Savoy Magazine Top 100 Influential African Americans in Corporate America (2014, 2016).
Clint holds a bachelor's degree in biology from Fairfield University and a Master of Business Administration degree in marketing from Fairleigh Dickinson University.
Caroline Manogue
Former EVP and Chief Legal Office, Endo Pharmaceuticals
Ms. Manogue is the former Executive Vice President and Chief Legal Officer of Endo International plc. Ms. Manogue started her career as a deal lawyer at Skadden. Endo was a client when it was still PE owned (by Kelso & Co.). She then moved over to Endo and was General Counsel for 15 years spanning a period that included the company going public through a reverse merger, multiple acquisitions, an inversion transaction, etc. She initially set up the compliance function at the company and was involved in all aspects of legal and regulatory oversight including being the Corporate Secretary. Caroline earned a JD from Fordham University and a BA, cum laude, from Middlebury College.